Lv0
0 积分 2026-05-30 加入
LBP-021 24-week safety and efficacy of brelovitug monotherapy for the treatment of chronic hepatitis D: data from phase 2b of AZURE-1
6小时前
求助中
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares
8小时前
已完结
Updates on Recent Advancements in Hepatitis D Virus Treatment
12天前
已完结
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D
12天前
已完结
WED-366 Characterization of BJT-778, an anti-HBsAg neutralizing monoclonal antibody for treatment of hepatitis B virus and hepatitis D virus infections
12天前
已完结
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
1个月前
已完结
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies
3个月前
已完结
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D
3个月前
已完结
皖公网安备34019202002308
